Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 10, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell

Download PDF AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 4, 2013– AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring that will refocus the company’s efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advancing key pipeline and preclinical assets. This restructuring is

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 15, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking

Download PDF FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 2, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 29, 2013– AVEO Oncology (NASDAQ: AVEO) today reported first quarter 2013 financial results. In lieu of a quarterly financial update conference call, the AVEO management team expects to host a conference call on May 2, 2013 following the review by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) of the company’s New Drug

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast

Download PDF Oncologic Drugs Advisory Committee Meeting Scheduled for May 2, 2013 CAMBRIDGE, Mass. & NORTHBROOK, Ill.–(BUSINESS WIRE)–Feb. 27, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company’s New Drug Application (NDA) for tivozanib for

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 20, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 13, 2013– AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments. “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA’s acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast